These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 8459986)

  • 21. Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
    Ann Oncol; 1994 Sep; 5(7):585-9. PubMed ID: 7993832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Bacchi M; Buser K; Kirchner V; Neuenschwander H; Orth B; Aapro MS; Thürlimann B
    Ann Oncol; 1994 Mar; 5(3):253-8. PubMed ID: 8186174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis.
    Roila F; Basurto C; Bracarda S; Sassi M; Lupattelli M; Picciafuoco M; Boschetti E; Tonato M; Del Favero A
    Eur J Cancer; 1991; 27(2):119-21. PubMed ID: 1827271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
    Fanning J; Hilgers RD
    Obstet Gynecol; 1994 Apr; 83(4):601-4. PubMed ID: 8134073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
    Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
    J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research.
    Tonato M
    Eur J Cancer; 1991; 27 Suppl 1():S12-4; discussion S22. PubMed ID: 1831628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
    Kris MG; Gralla RJ; Clark RA; Tyson LB; Fiore JJ; Kelsen DP; Groshen S
    Cancer Treat Rep; 1985 Nov; 69(11):1257-62. PubMed ID: 3912039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
    Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
    Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial.
    Chua DT; Sham JS; Au GK; Choy D; Kwong DL; Yau CC; Cheng AC
    Br J Clin Pharmacol; 1996 May; 41(5):403-8. PubMed ID: 8735681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
    Sledge GW; Einhorn L; Nagy C; House K
    Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
    Ballatori E; Roila F; Berto P; De Angelis V; Neri C; Olivieri A; Tonato M; Del Favero A
    Pharmacoeconomics; 1994 Mar; 5(3):227-37. PubMed ID: 10146897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial.
    Kris MG; Gralla RJ; Clark RA; Tyson LB; Groshen S
    Cancer; 1987 Dec; 60(11):2816-22. PubMed ID: 3315176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ondansetron against metoclopramide/dexamethasone--a comparative study.
    Lim AK; Haron MR; Yap TM
    Med J Malaysia; 1994 Sep; 49(3):231-8. PubMed ID: 7845271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
    Fox SM; Einhorn LH; Cox E; Powell N; Abdy A
    J Clin Oncol; 1993 Dec; 11(12):2391-5. PubMed ID: 8246028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
    Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D
    Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
    Kaizer L; Warr D; Hoskins P; Latreille J; Lofters W; Yau J; Palmer M; Zee B; Levy M; Pater J
    J Clin Oncol; 1994 May; 12(5):1050-7. PubMed ID: 8164029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.
    Roila F; Tonato M; Basurto C; Picciafuoco M; Bracarda S; Donati D; Malacarne P; Monici L; Di Costanzo F; Patoia L
    J Clin Oncol; 1989 Nov; 7(11):1693-700. PubMed ID: 2681556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.